Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.700
-0.160 (-8.60%)
At close: Jun 5, 2026, 4:00 PM EDT
1.790
+0.090 (5.29%)
After-hours: Jun 5, 2026, 6:33 PM EDT

Gain Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
7313559533765
Market Cap Growth
28.44%131.17%10.59%42.48%-42.36%-
Enterprise Value
56.64115.1548.636.8817.9928.93
Last Close Price
1.703.222.163.273.135.43
PS Ratio
---960.42265.47391.09
PB Ratio
5.167.307.984.211.971.85
P/TBV Ratio
4.415.726.733.381.971.59
EV/Sales Ratio
---668.36128.43175.35
Debt / Equity Ratio
0.030.030.050.050.050.04
Net Debt / Equity Ratio
-1.13-1.08-1.33-1.25-1.00-1.01
Net Debt / EBITDA Ratio
0.811.080.480.711.072.55
Net Debt / FCF Ratio
0.821.090.520.841.272.83
Asset Turnover
-000.000.000.01
Quick Ratio
4.266.222.663.394.8814.45
Current Ratio
4.696.632.973.595.1114.78
Return on Equity (ROE)
-130.42%-155.66%-204.95%-141.57%-65.52%-67.73%
Return on Assets (ROA)
-99.19%-111.87%-136.01%-104.58%-56.66%-56.93%
Return on Invested Capital (ROIC)
-687.47%-592.68%-525.93%-448.06%-407.92%-550.46%
Return on Capital Employed (ROCE)
-114.78%-135.20%-186.09%-132.33%-63.03%-62.96%
Buyback Yield / Dilution
-42.24%-44.08%-75.86%-9.49%-16.90%-279.11%
Total Shareholder Return
-42.24%-44.08%-75.86%-9.49%-16.90%-279.11%
SEC Filings: 10-K · 10-Q